Market Place
Sourcing Support
Annora`s Generic Glycerol Phenylbutyrate Receives Approval in the U.S.
09 Aug 2022 //
FDA
The top 10 most-expensive meds in the U.S.—and they`re not the usual suspects
13 Jun 2019 //
FIERCE PHARMA
Horizon Pharma Announces FDA Approval of RAVICTI® (glycerol phenylbutyrate) Oral
28 Dec 2018 //
BUSINESSWIRE
Sobi secures NHS reimbursement for Ravicti
23 Aug 2018 //
PHARMA TIMES
Raviciti® (glycerol phenylbutyrate) : Horizon Therapeutics v. Par Pharmaceutical
11 Aug 2018 //
PATENT LITIGATION
Horizon Pharma Announces USPTO Issuance Covering Ravicti Oral Liquid
17 Jul 2018 //
BUSINESSWIRE
Horizon Announces the U.S. Patent & Trademark inssue notice RAVICTI® Oral Liquid
16 Jul 2018 //
PRESS RELEASE
With FDA nod, BioMarin prices orphan drug Brineura at $702,000
28 Apr 2017 //
FIERCE PHARMA
Sobi & Horizon enter five-year distribution agreement for Ravicti & Ammonaps
07 Dec 2016 //
PR NEWSWIRE
More Rare Disease Deal making to Follow Horizon`s Raptor Deal
13 Sep 2016 //
THE STREET
Horizon Theraps Ravicti (Glycerol Phenylbutyrate) Approved in US
08 Sep 2016 //
FDA
Approved Drug, 4-PBA, Eased ER Stress & Artery Pressure in PAH Rat Model
27 Jun 2016 //
PULMONARYHYPERTENSIONNEWS
Horizon Receives Health Canada Approval for Ravicti
21 Mar 2016 //
MARKET WIRED
Horizon to Buy Hyperion for $1.1 Billion, Gain Orphan Drugs
31 Mar 2015 //
BLOOMBERG BUSINESS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.